Abstract:Background: Small retrospective series suggest that local consolidative treatment (LCT) may improve survival in oligometastatic pancreatic ductal adenocarcinoma (PDAC). However, no uniform definition of oligometastatic disease (OMD) in PDAC exists; this impedes meaningful conclusions. Patients and methods: A systematic literature search using PubMed, Web of Science, and Cochrane CENTRAL registries for studies and protocols reporting on definitions and/or LCT of OMD in PDAC was performed. The primary endpoint was the definition of OMD. Levels of agreement were categorized as consensus (≥75% agreement between studies), fair agreement (50%-74%), and absent/poor agreement (<50%). Results: After screening of 5374 abstracts, the full text of 218 studies was assessed, of which 76 were included in the qualitative synthesis. The majority of studies were retrospective (n = 66, 87%), two were prospective studies and eight were study protocols. Studies investigated mostly liver (n = 38, 51%) and lung metastases (n = 15, 20%). Across studies, less than one-half (n = 32, 42%) reported a definition of OMD, while 44 (58%) did not. Involvement was limited to a single organ (consensus). Additional criteria for defining OMD were the number of lesions (consensus), metastatic site (poor agreement), metastatic size (poor agreement), treatment possibilities (poor agreement), and biomarker response (poor agreement). Liver OMD could involve three or fewer lesions (consensus) and synchronous disease (fair agreement), while lung metastases could involve two or fewer lesions and metachronous disease (consensus). The large majority of studies were at a high risk of bias or did not include any control groups. Conclusion: Definitions of OMD were not used or varied widely between studies hampering across-study comparability and highlighting an unmet need for a consensus. The present study is part of a multistep process that aims to develop an interdisciplinary consensus on OMD in pancreatic cancer.

Defining oligometastatic state in uro-oncological cancers

Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology

Oligometastatic Disease in Prostate Cancer. Evolving paradigm: current knowledge, diagnostic techniques and treatment strategies

Oligometastatic Prostate Cancer: Current Status and Future Challenges

Oligometastasis and oligo-recurrence: more than a mirage

Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches

Tumor Biology and Multidisciplinary Strategies of Oligometastasis in Gastrointestinal Cancers

Oligometastasis: Expansion of Curative Treatments in the Field of Oncology

Oligometastatic prostate cancer: local treatment and metastasis-directed therapy

Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis

Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease?

Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition

Role of Metastasis-Directed Therapy in Genitourinary Cancers

Neoplasm Oligometastasis and Its Therapeutic Strategies

Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer

Abstract 3405: MicroRNA Expression Characterizes Oligometastasis(es)

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer

Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure

Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer